Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation.

Authors:
Dr. Theodore Lemuel Mathuram, PhD
Dr. Theodore Lemuel Mathuram, PhD
Nova Southeastern University
Research Associate
Toxicology, Cancer Drug screening
Davie, Florida | United States
Vilwanathan Ravikumar
Vilwanathan Ravikumar
University of Madras
India
Lisa M Reece
Lisa M Reece
University of Texas Medical Branch at Galveston
United States
Selvaraju Karthik
Selvaraju Karthik
School of Life Sciences
Dr Changam Sheela Sasikumar, PhD
Dr Changam Sheela Sasikumar, PhD
Affiliated to University of Madras
Chief scientific Officer
Biochemistry Molecular Biology
Chennai, Tamil nadu | India
Kotturathu Mammen Cherian
Kotturathu Mammen Cherian
Institute of Cardiovascular Diseases
India

Environ Toxicol Pharmacol 2016 Sep 20;46:194-205. Epub 2016 Jul 20.

Department of Cardiothoracic Surgery, Frontier Lifeline Hospital, Chennai 600101, Tamil Nadu, India.

Neuroblastoma is the most common tumor amongst children amounting to nearly 15% of cancer deaths. This cancer is peculiar in its characteristics, exhibiting differentiation, maturation and metastatic transformation leading to poor prognosis and low survival rates among children. Chemotherapy, though toxic to normal cells, has shown to improve the survival of the patient with emphasis given more towards targeting angiogenesis. Recently, Tideglusib was designed as an 'Orphan Drug' to target the neurodegenerative Alzheimer's disease and gained significant momentum in its function during clinical trials. Duffy et al. recently reported a reduction in cell viability of human IMR32 neuroblastoma cells when treated with Tideglusib at varying concentrations. We investigated the effects of Tideglusib, at various concentrations, compared to Lithium chloride at various concentrations, on IMR32 cells. Lithium, a known GSK-3 inhibitor, was used as a standard to compare the efficiency of Tideglusib in a dose-dependent manner. Cell viability was assessed by MTT assay. The stages of apoptosis were evaluated by AO/EB staining and nuclear damage was determined by Hoechst 33258 staining. Reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm) were assessed by DCFDA dye and Rhodamine-123 dye, respectively. Tideglusib reported a significant dose-dependent increase in pro-apoptotic proteins (PARP, Caspase-9, Caspase-7, Caspase-3) and tumor-related genes (FasL, TNF-α, Cox-2, IL-8, Caspase-3). Anti-GSK3 β, pGSK3 β, Bcl-2, Akt-1, p-Akt1 protein levels were observed with cells exposed to Tideglusib and Lithium chloride. No significant dose-dependent changes were observed for the mRNA expression of collagenase MMP-2, the tumor suppressor p53, or the cell cycle protein p21. Our study also reports Tideglusib reducing colony formation and increasing the level of sub-G0/G1 population in IMR32 cells. Our investigations report the significance of Tideglusib as a promising apoptotic inducer in human neuroblastoma IMR32 cells. Our study also reports that LiCl reduced cell viability in IMR32 cells inducing apoptosis mediated by ROS generation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.etap.2016.07.013DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
September 2016
48 Reads
3 Citations
1.862 Impact Factor

Publication Analysis

Top Keywords

imr32 cells
20
cell viability
12
tideglusib
9
cells
8
study reports
8
ros generation
8
neuroblastoma imr32
8
lithium chloride
8
human neuroblastoma
8
imr32
6
tideglusib dose-dependent
4
dose-dependent manner
4
manner cell
4
efficiency tideglusib
4
viability assessed
4
cell cycle
4
inhibitor standard
4
cycle protein
4
standard compare
4
p53 cell
4

Similar Publications